Results 31 to 40 of about 5,474,833 (393)

Does sex of the patient play a role in survival for MSI colorectal cancer? [PDF]

open access: yes, 2018
Microsatellite instability (MSI) is a feature of colorectal tumors that develops as a result of inactivation of the DNA mismatch repair system. It is found in about 15% of all colorectal cancers and is an important prognostic molecular marker when ...
Alecu, Lucian   +11 more
core   +7 more sources

Analysis of adenoma detection rate of colonoscopy among trainees [PDF]

open access: yesAnnals of Coloproctology
Purpose To analyze adenoma detection rate (ADR) and related quality indicators of colonoscopy among trainees and make recommendations for appropriate colonoscopy training.
Young Min Song   +7 more
doaj   +1 more source

Establishment and validation of a novel nomogram incorporating clinicopathological parameters into the TNM staging system to predict prognosis for stage II colorectal cancer

open access: yesCancer Cell International, 2020
Background Survival outcomes are significantly different in stage II colorectal cancer (CRC) patients with diverse clinicopathological features. The objective of this study is to establish a credible prognostic nomogram incorporating easily obtained ...
Shaobo Mo   +7 more
doaj   +1 more source

Size and number of lymph nodes were risk factors of recurrence in stage II colorectal cancer

open access: yesBMC Cancer, 2023
Background Size and number of lymph nodes (LNs) were reported to be associated with the prognosis of stage II colorectal cancer (CRC). The purpose of this study was to determine the prognostic role of the size of LNs (SLNs) measured by computer ...
Shanyou Tong   +6 more
doaj   +1 more source

Colorectal cancer statistics, 2017

open access: yesCa, 2017
Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every 3 years, the American Cancer Society provides an update of CRC incidence, survival, and mortality rates and trends.
R. Siegel   +6 more
semanticscholar   +1 more source

Convolutional Neural Network-Based Automatic Classification of Colorectal and Prostate Tumor Biopsies Using Multispectral Imagery: System Development Study [PDF]

open access: yesJMIR Bioinform Biotech 2022, 2023
Colorectal and prostate cancers are the most common types of cancer in men worldwide. To diagnose colorectal and prostate cancer, a pathologist performs a histological analysis on needle biopsy samples. This manual process is time-consuming and error-prone, resulting in high intra and interobserver variability, which affects diagnosis reliability. This
arxiv   +1 more source

A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis

open access: yesCancers, 2021
Simple Summary According to the available data, colorectal cancer (CRC) is one of the most common malignant neoplasms. Depending on the location, type of cancer or gender, it is ranked 2nd to 4th in terms of incidence in the world.
T. Sawicki   +5 more
semanticscholar   +1 more source

BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. [PDF]

open access: yes, 2016
The proteasome inhibitor MLN9708 is an orally administered drug that is hydrolyzed into its active form, MLN2238 (ixazomib). Compared with Bortezomib, MLN2238 has a shorter proteasome dissociation half-life and a lower incidence and severity of ...
Barkhouse, Darryll   +7 more
core   +2 more sources

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

open access: yesJournal of Experimental & Clinical Cancer Research, 2018
Background Precision medicine calls for an early indicator of treatment efficiency. Circulating tumor DNA (ctDNA) is a promising marker in this setting. Our prospective study explored the association between disease development and change of ctDNA during
C. B. Thomsen   +5 more
doaj   +1 more source

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

open access: yesNew England Journal of Medicine, 2004
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS Of 813 patients
H. Hurwitz   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy